Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Autor: Anastasiou P; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Moore C; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Rana S; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Tomaschko M; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Pillsbury CE; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., de Castro A; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Boumelha J; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Mugarza E; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., de Carné Trécesson S; Oncogene Biology Laboratory, Francis Crick Institute, London, UK., Mikolajczak A; Experimental Histopathology, Francis Crick Institute, London, UK., Blaj C; Revolution Medicines, Inc., Redwood City, CA, USA., Goldstone R; Bioinformatics & Biostatistics Science Technology Platform, Francis Crick Institute, London, UK., Smith JAM; Revolution Medicines, Inc., Redwood City, CA, USA., Quintana E; Revolution Medicines, Inc., Redwood City, CA, USA., Molina-Arcas M; Oncogene Biology Laboratory, Francis Crick Institute, London, UK. miriam.molina@crick.ac.uk., Downward J; Oncogene Biology Laboratory, Francis Crick Institute, London, UK. julian.downward@crick.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2024 Sep 25; Vol. 15 (1), pp. 8146. Date of Electronic Publication: 2024 Sep 25.

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.

Autor: Caswell DR; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. deborah.caswell@crick.ac.uk., Gui P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Mayekar MK; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Law EK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Bailey C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Boumelha J; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Manabe T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Martinez-Ruiz C; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Bakker B; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., De Dios Palomino Villcas J; Core Research Laboratory, ISPRO, Florence, Italy., I Vokes N; Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dietzen M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Gini B; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Tamaki W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Allegakoen P; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Humpton TJ; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK.; CRUK Beatson Institute, Glasgow, UK.; Glasgow Caledonian University, Glasgow, UK., Hill W; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Tomaschko M; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Lu WT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Haderk F; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Al Bakir M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Nagano A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Gimeno-Valiente F; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., de Carné Trécesson S; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Vendramin R; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Barbè V; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Mugabo M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Weeden CE; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., McCoach CE; Genentech Inc, South San Francisco, CA, USA., Almeida B; The Roger Williams Institute of Hepatology, Foundation for Liver Research, London, UK.; Faculty of Life Sciences & Medicine, King's College London, London, UK., Green M; Experimental Histopathology, The Francis Crick Institute, London, UK., Gomez C; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Nanjo S; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Barbosa D; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Moore C; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Przewrocka J; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Black JRM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Grönroos E; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Suarez-Bonnet A; Experimental Histopathology, The Francis Crick Institute, London, UK.; Department of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK., Priestnall SL; Experimental Histopathology, The Francis Crick Institute, London, UK.; Department of Pathobiology & Population Sciences, The Royal Veterinary College, London, UK., Zverev C; Biological Research Facility, The Francis Crick Institute, London, UK., Lighterness S; Biological Research Facility, The Francis Crick Institute, London, UK., Cormack J; Biological Research Facility, The Francis Crick Institute, London, UK., Olivas V; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Cech L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Andrews T; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Rule B; Cursorless, London, UK., Jiao Y; Novogene Europe, Cambridge, UK., Zhang X; Novogene Europe, Cambridge, UK., Ashford P; Institute of Structural and Molecular Biology, University College London, London, UK., Durfee C; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA., Venkatesan S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Temiz NA; Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA.; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Tan L; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Larson LK; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Argyris PP; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA.; School of Dentistry, University of Minnesota, Minneapolis, MN, USA.; College of Dentistry, Ohio State University, Columbus, OH, USA., Brown WL; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA., Yu EA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.; Sutter Health Palo Alto Medical Foundation, Department of Pulmonary and Critical Care, Mountain View, CA, USA., Rotow JK; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Guha U; Thoracic and GI Malignancies Branch, NCI, NIH, Bethesda, MD, USA.; NextCure Inc., Beltsville, MD, USA., Roper N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yu J; Biomedical Sciences Program, University of California, San Francisco, San Francisco, CA, USA., Vogel RI; Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Thomas NJ; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Marra A; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology IRCCS, Milan, Italy., Selenica P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Yu H; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Medicine, Weill Cornell College of Medicine, New York City, NY, USA., Bakhoum SF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Chew SK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK., Reis-Filho JS; Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK.; Department of Medical Oncology, University College London Hospitals, London, UK., Vousden KH; p53 and Metabolism Laboratory, The Francis Crick Institute, London, UK., McGranahan N; Cancer Genome Evolution Research Group, University College London, Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kanu N; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK., Harris RS; Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX, USA.; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX, USA., Downward J; Oncogene Biology Laboratory, The Francis Crick Institute, London, UK., Bivona TG; Departments of Medicine and Cellular and Molecular Pharmacology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. trever.bivona@ucsf.edu.; Chan Zuckerberg Biohub, San Francisco, CA, USA. trever.bivona@ucsf.edu., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.

Publikováno v: Nature genetics [Nat Genet] 2024 Jan; Vol. 56 (1), pp. 60-73. Date of Electronic Publication: 2023 Dec 04.

The Proteomic Analysis of Cancer-Related Alterations in the Human Unfoldome.

Autor: Paromov, Victor¹ (AUTHOR) vparomov@mmc.edu, Uversky, Vladimir N.² (AUTHOR) vuversky@usf.edu, Cooley, Ayorinde³ (AUTHOR) acooley@mmc.edu, Liburd II, Lincoln E.⁴ (AUTHOR) smukherjee@mmc.edu, Mukherjee, Shyamali⁴ (AUTHOR), Na, Insung² (AUTHOR) nais8303@gmail.com, Dayhoff II, Guy W.⁵ (AUTHOR) gdayhoff@usf.edu, Pratap, Siddharth^1,3 (AUTHOR) spratap@mmc.edu

Publikováno v: International Journal of Molecular Sciences. Feb2024, Vol. 25 Issue 3, p1552. 21p.

Machine learning to predict distant metastasis and prognostic analysis of moderately differentiated gastric adenocarcinoma patients: a novel focus on lymph node indicators.

Autor: Kangping Yang, Jiaqiang Wu, Tian Xu, Yuepeng Zhou, Wenchun Liu, Liang Yang

Publikováno v: Frontiers in Immunology; 2024, p1-21, 21p

Work in Progress: Toward an Augmented Reality (AR) Learning Environment for Hispanic High School Students to Visualize and Embody STEM Spatial Transformations.

Autor: Tillman, Daniel A.¹, Wei Yan², Song An¹, Liew, Jeffrey¹, Lim, Kien H.¹, Garbrecht, Lisa³, Yasskin, Philip B.³

Publikováno v: Proceedings of the ASEE Annual Conference & Exposition. 2023, p1-5. 5p.